Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AdvisorShares Dorsey Wright Short ETF (NQ:DWSH)

5.920 +0.060 (+1.02%)
Delayed Quote Updated: 10:43 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AdvisorShares Dorsey Wright Short ETF

News headline image
This Stock Is Among The Laggards In Social Media Companies — Here’s What Wall Street Expects From Its Q4 Earnings Tomorrow ↗
Snap shares have fallen nearly 45% over the past 12 months, only better than DJT, Sprout Social and Bumble over the same period. 
Via Stocktwits
Snap Shares Are Tumbling Today As Focus Turns To Q4 Earnings – What Are Investors Expecting? ↗
Via Stocktwits
News headline image
WHR Slips 7% — Why Is Retail Expecting Whirlpool To Eliminate Dividend? ↗
Whirlpool reported fourth quarter adjusted earnings per share of $1.10, which fell well short of Wall Street consensus of $1.52 per share, according to data from fiscal.ai. 
Via Stocktwits
Topics Earnings
SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns ↗
Via Stocktwits
News headline image
Why Did Coty Offload Wella From Its Portfolio? ↗
Coty has sold its remaining 25.8% stake in Wella to KKR-managed capital accounts and investment affiliates for an upfront cash payment of $775 million. 
Via Stocktwits
Topics Economy Initial Public Offering
Merck Stock Rises Upon Receipt Of $700M In Funding For Experimental Cancer Drug ↗
Via Stocktwits
Humana Stock Rises After Insurer Reaffirms Full-Year Earnings Guidance ↗
Via Stocktwits
VF Corp To Sell Dickies Brand To Bluestar Alliance For $600M ↗
Via Stocktwits
News headline image
Why Is SRPT Stock Falling Today? ↗
Sarepta Therapeutics announced a debt refinancing plan totaling about $291 million. 
Via Stocktwits
News headline image
Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys ↗
The data from the study cohort will be used to determine whether administering sirolimus before and after the ELEVIDYS infusion can help reduce acute liver injury, the company said. 
Via Stocktwits
News headline image
Thermo Fisher To Acquire Clario Holdings In A $9.4B Deal ↗
Thermo Fisher expects the acquisition to be immediately accretive to its adjusted operating margin. 
Via Stocktwits
News headline image
Illumina Stock Surged 6% Today – Here’s Why ↗
The company announced that its new business will focus on developing data assets, software, and artificial intelligence to drive drug development. 
Via Stocktwits
Topics Artificial Intelligence
Campbell’s Gains Wall Street Confidence With Multiple Price Target Hikes, Retail Chatter Surges ↗
Via Stocktwits
This Pharma Stock Shot Up 8% Today, Gets A Price Target Hike From Wells Fargo: Here’s Why Retail Sees Opportunity ↗
Via Stocktwits
Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported Earlier ↗
Via Stocktwits
News headline image
Sarepta Just Got A Good Restructuring Deal For $700M Debt, But Stock Tumbles 7% – Here’s Why ↗
Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal. 
Via Stocktwits
News headline image
This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point ↗
Truist, however, kept a ‘Buy’ rating on the shares. 
Via Stocktwits
News headline image
Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys ↗
JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target. 
Via Stocktwits
Topics Death
News headline image
Regeneron’s Therapy For Blood Cancer Bags FDA Approval: REGN Stock Jumps ↗
While Lynozyfic was granted accelerated approval based on response rate in the LINKER-MM1 trial, continued approval may depend upon verification and description of clinical benefit in a confirmatory... 
Via Stocktwits
Topics Death
News headline image
5 Low-Risk ETFs To Buy Amid Historic Bond Turmoil ↗
Investors are increasingly exploring diversified strategies that help to protect their portfolios from downside risk. 
Via Talk Markets
Topics ETFs
News headline image
Wall Street Tumbles On Renewed Fears: 5 ETFs Standing Tall ↗
Though terrible trading in the stock world pushed the ETF space into deep red on the day, a few ETFs still saw strength. 
Via Talk Markets
News headline image
5 ETFs That Gained Double Digits in Q2 ↗
These funds have been the quarter’s star performers and could also be winners next quarter if the current trends continue. 
Via Talk Markets
News headline image
5 ETFs That Gained Double Digits In Q2 ↗
While most corners of the market were deep in the red, a few have performed well. Let's take a look at the ETFs that have been the quarter’s star performers, as they could also be winners next quarter... 
Via Talk Markets
News headline image
Forget Recession Fears With These ETFs ↗
Here are five ETFs that could provide some shelter from the crisis and benefit investors’ portfolio. 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.